Table 1.

The top most frequent copy number gain and loss in both SALS patient subgroups.

	SALS1 patients						SALS2 patients
	Chr.	Start	Stop	Aberration Size (bps)	Frequency (%)	NeuroArray genes	Chr.	Start	Stop	Aberration Size (bps)	Frequency (%)	NeuroArray genes
DUPLICATIONS	14	31552632	31552690	59	76.47	AP4S1	14	31552632	31552690	59	76.92	AP4S1
	17	17716576	17720711	4136	70.59	SREBF1	17	17716576	17720711	4136	69.23	SREBF1
	X	122318451	122336599	18149	70.59	GRIA3	22	24376158	24384300	8143	69.23	GSTT1
	X	122318291	122318451	161	64.71	GRIA3	17	17720711	17726812	6102	61.54	SREBF1
	7	100493729	100493862	134	58.82	ACHE	9	129272014	129458220	186207	53.85	LMX1B
	X	122318031	122318291	261	58.82	GRIA3	9	131388073	131394672	6600	53.85	—
	X	122336599	122459975	123377	58.82	GRIA3	17	17715816	17716576	761	53.85	SREBF1
	17	17720711	17726812	6102	52.94	SREBF1	1	55331123	55527185	196063	46.15	DHCR24, PCSK9
	7	100488043	100490289	2247	47.06	ACHE	2	127807997	128439169	631173	46.15	BIN1, LIMS2
	7	100493373	100493729	357	47.06	ACHE	2	241657356	241728764	71409	46.15	KIF1A
	9	131388073	131394672	6600	47.06	—	5	176853852	176869527	15676	46.15	GRK6
DELETIONS	1	47716828	47775972	59145	88.24	STIL	3	155547586	155560259	12674	69.23	SLC33A1
	20	33986975	35569474	1582500	88.24	UQCC, NFS1, PHF20, EPB41L1, DLGAP4, NDRG3, TLDC2, SAMHD1	20	33986975	35575306	1588332	69.23	UQCC, NFS1, PHF20, EPB41L1, DLGAP4, NDRG3, TLDC2, SAMHD1
	20	35569474	35575306	5833	82.35	SAMHD1	1	47767175	47770585	3411	61.54	STIL
	1	47435653	47716828	281176	76.47	STIL	18	9117815	9134199	16385	61.54	NDUFV2
	2	32339724	32429834	90111	76.47	SPAST, SLC30A6	3	155560259	155560361	103	53.85	SLC33A1
	3	155551254	155560202	8949	76.47	SLC33A1	12	111956174	111993684	37511	53.85	ATXN2
	9	128001127	128001733	607	76.47	HSPA5	1	47435653	47767175	331523	46.15	STIL
	1	47775972	47776133	162	70.59	STIL	1	47770585	47770755	171	46.15	STIL
	2	32323849	32339724	15876	70.59	SPAST, SLC30A6	2	32314495	32409410	94916	46.15	SPAST, SLC30A6
	2	32429834	32432100	2267	70.59	SPAST, SLC30A6	10	70432579	70441196	8618	46.15	TET1
	3	155547586	155551254	3669	70.59	SLC33A1	14	92527804	92562372	34569	46.15	ATXN3

The table lists the gains and losses that occurred in at least 10% of the two previously characterized transcriptome-based SALS subgroups. The chromosomal regions, including the start and end positions, aberration size, frequency in SALS patients and CNV embedded NeuroArray genes are listed. Chromosomal positions are referred to the human reference sequence hg19 assembly. Genes previously identified as potential risk factors in ALS are in bold.